Hamilton, Canada Clinical Trials

A listing of Hamilton, Canada clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 106 clinical trials
featured
A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy (SAPPHIRE)

This is an open-label, randomized (1:1), multicenter, Phase 3 clinical trial evaluating the safety and efficacy of nivolumab in combination with investigational agent sitravatinib compared to docetaxel in patients with advanced non-squamous NSCLC who have previously experienced radiographic disease progression on or after treatment with platinum-based chemotherapy in combination with …

platinum-based chemotherapy
lung carcinoma
cancer chemotherapy
experimental drug
docetaxel
Juravinski Cancer Centre
 (1.6 away) Contact site
  • 213 views
  • 28 Jul, 2021
  • +188 other locations
featured
COMMANDS - Myelodysplastic Syndromes (MDS) - ACE536-MDS-002 – Canada  

The study will be conducted in compliance with the International Council for Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good Clinical Practice (GCP) and applicable regulatory requirements.   This is an interventional active-controlled, open-label, randomized Phase 3 study to compare the efficacy and safety of luspatercept …

epoetin alfa
Juravinski Cancer Centre
 (1.6 away)
  • 33 views
  • 03 Aug, 2021
  • +9 other locations
Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC

Sometimes, cancer patients receive an initial treatment, followed by additional treatment to lower the chance of cancer coming back. The standard or usual treatment for this type of disease is initially having radiation therapy at the same time as chemotherapy (with a drug called cisplatin), with no additional therapy afterwards

pet/ct scan
carcinoma
human papillomavirus
neutrophil count
oropharyngeal carcinoma
Juravinski Cancer Centre at Hamilton Health Sciences
 (1.6 away) Contact site
  • 56 views
  • 24 Jul, 2021
  • +29 other locations
Study of Subcutaneous Risankizumab Injection Compared to Oral Apremilast Tablets to Assess Change in Disease Activity And Adverse Events in Adult Participants With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy

Psoriasis (PsO) is a chronic disease characterized by marked inflammation of the skin that results in thick, red, scaly plaques. This study will assess how safe and effective risankizumab is compared to apremilast in adult participants with moderate plaque psoriasis. Adverse events and change in disease symptoms will be monitored. …

arthritis
apremilast
risankizumab
systemic therapy
plaque psoriasis
Dermatrials Research /ID# 230119
 (0.4 away) Contact site
  • 0 views
  • 04 Aug, 2021
  • +61 other locations
Rofecoxib Efficacy and Safety Evaluation Trial in Hemophilic Arthropathy

This is a multicenter, randomized, double-blind study to evaluate the efficacy and safety of TRM-201 (rofecoxib) versus Placebo in the treatment of patients with hemophilic arthropathy (HA) over a 12-week period (Part I) that is followed by a year-long (52 week) open-label extension (Part II) to further evaluate the safety …

Rainbow Babies and Children's Hospital
 (149.2 away) Contact site
  • 0 views
  • 02 Aug, 2021
  • +50 other locations
A Phase 3 Multi-Center Randomized Double-Blind Placebo-Controlled Study of Fostamatinib Disodium in the Treatment of wAIHA

The primary objective of this study is to assess the efficacy of fostamatinib in subjects with warm antibody autoimmune hemolytic anemia (wAIHA).

Hamilton Health Sciences- McMaster University Medical Centre
 (2.4 away) Contact site
  • 113 views
  • 31 Jul, 2021
  • +125 other locations
Pembrolizumab Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)

This is a randomized, double-blind, study that compares pembrolizumab with placebo given as adjuvant therapy in participants with high-risk locally advanced cutaneous squamous cell carcinoma (LA cSCC) that have undergone surgery with curative intent in combination with radiotherapy. The primary hypothesis is that pembrolizumab is superior to placebo in increasing …

adjuvant therapy
mk-3475
cancer
pembrolizumab
Juravinski Cancer Center ( Site 0151)
 (1.6 away) Contact site
  • 69 views
  • 03 Aug, 2021
  • +146 other locations
Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab.

This is a randomized, double blind, active-controlled, parallel group, multicenter 52-week Phase 3 study to compare the efficacy and safety of benralizumab 30 mg versus mepolizumab 300 mg administered by subcutaneous (SC) injection in patients with relapsing or refractory EGPA on corticosteroid therapy with or without stable immunosuppressive therapy. All …

immunosuppression
prednisone
nasal abnormality
steroid therapy
remission
Research Site
 (0.5 away) Contact site
  • 21 views
  • 03 Aug, 2021
  • +80 other locations
Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer

This study is being done to see how well two drugs (enfortumab vedotin and pembrolizumab) work together to treat patients with urothelial cancer. The study will compare these drugs to other drugs that are usually used to treat this cancer (standard of care). The patients in this study will have …

measurable disease
metastatic urothelial carcinoma
systemic therapy
pembrolizumab
carcinoma
Site CA11002
 (1.7 away) Contact site
  • 5 views
  • 21 Jul, 2021
  • +111 other locations
Study to Gather Information About the Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following an Acute Heart Attack

The purpose of this study is to try to find the best dose of the new drug BAY 2433334 to give to participants and to look at how well BAY 2433334 works on top of a dual antiplatelet therapy (acetylsalicylic acid +/- clopidogrel) in patients following a recent heart attack …

ck-mb
angiography
antiplatelet therapy
troponin
aspirin
Hamilton General Hospital
 (0.9 away) Contact site
  • 57 views
  • 04 Aug, 2021
  • +192 other locations